Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) has announced its phase one clinical trial for PD1-Vaxx will proceed to the second dose cohort
- This follows a review by the Cohort Review Committee (CRC) who confirmed the immunotherapy drug candidate is safe with no dose-limiting and no serious adverse reactions
- PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer and produce an anti-cancer effect
- This second dose cohort will administer patients with a mid-dose level of 50 micrograms — an increase from the previous 10 microgram dose
- The primary goal of the phase one trial is to determine safety and an optimal dose as a monotherapy
- Company shares are up 4.76 per cent and are trading at 11 cents
Imugene (IMU) has announced the Cohort Review Committee (CRC) has confirmed its phase one clinical trial for PD1-Vaxx will proceed to the second dose cohort.
After a review of patient data, the CRC agreed Imugene’s immunotherapy drug candidate is safe with no dose-limiting and no serious adverse reactions.
PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer and produce an anti-cancer effect.
Imugene may now proceed with opening the second PD1-Vaxx cohort at a mid-dose level of 50 micrograms after the first phase patients were dosed with just 10 micrograms.
“The Cohort Review Committee for the study today reviewed the first low dose cohort of patient’s data and has recommended to proceed to the next dose escalation due to safety and tolerability,” Cabrini Hospital Principal Investigator Professor Gary Richardson said.
Clinicians will also determine if PD1-Vaxx as a monotherapy in patients who’ve progressed on standard of care immune checkpoint inhibitors will prolong survival, delay tumour progression or reduce the tumour in lung cancer patients.
The primary goal of the phase one trial is to determine safety and an optimal dose as a monotherapy. The CRC will also measure and review the efficacy, tolerability and immune response of the new dose.
“Everyone supporting the study who are involved in developing this important new cancer therapy are very encouraged by the progress to date. We look forward to continuing this study and reporting to the market of its progress,” Imugene Managing Director and CEO Leslie Chong said.
Company shares are up 4.76 per cent and are trading at 11 cents at 11:03 am AEDT.
